Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Limited phase I study of morphine-3-glucuronide.

R T Penson1, S P Joel, S Clark

  • 1Division of Hematology/Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, Massachusetts 02114, USA. rpenson@partners.org

Journal of Pharmaceutical Sciences
|December 18, 2001
PubMed
Summary

Morphine-3-glucuronide (M3G) showed minimal toxicity in healthy volunteers at tested doses. This study found no significant adverse effects or changes in vital signs, indicating M3G is well-tolerated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.

Gynecologic oncology·2019
Same author

A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.

Gynecologic oncology·2016
Same author

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Bevacizumab and ovarian cancer.

Drugs of today (Barcelona, Spain : 1998)·2011

Area of Science:

  • Pharmacology
  • Clinical Toxicology

Background:

  • Morphine-3-glucuronide (M3G) is a major metabolite of morphine.
  • Understanding M3G toxicity is crucial for pain management and opioid pharmacokinetics.

Purpose of the Study:

  • To investigate the toxicity and pharmacokinetics of intravenous morphine-3-glucuronide (M3G) in healthy volunteers.
  • To assess potential neuroexcitatory and opioid effects of M3G at single doses.

Main Methods:

  • Open, uncontrolled, single-blinded, single-dose study.
  • Three cohorts of healthy volunteers (n=3 per cohort) received 7.5, 15, or 30 mg/70 kg IV M3G.
  • Plasma M3G concentrations measured via HPLC; subjective toxicity and vital signs recorded over 24 hours.

Main Results:

Related Experiment Videos

  • No significant changes in cardiovascular or respiratory parameters were observed.
  • Subjective toxicity assessments revealed virtually no adverse effects.
  • Pharmacokinetics followed a two-compartment model with a mean elimination half-life of 1.66 hours.

Conclusions:

  • M3G demonstrated a favorable safety profile at the investigated doses.
  • No clear neuroexcitatory or opioid effects were detected.
  • M3G pharmacokinetics were comparable to those of morphine-6-glucuronide (M6G).